Evidera’s Post

Restoring T cell production in thymus following injury Thymus is known to generate broad T cell repertoire in response to diverse stimuli like, infection, stress, pregnancy, malnutrition, drug use and cytoreductive chemotherapy. Thymus also has a tremendous regenerative capacity. Delay to this recovery after acute damage may have important clinical effects. Multiple distinct pathways of regeneration and the molecular mechanisms that trigger these pathways after damage have been reported recently. The researchers in this Review, discuss the effects of different types of damage to the thymus, and the cellular and molecular mechanisms that regulate endogenous tissue regeneration in the thymus. They also highlight some of the clinical challenges that are presented by dysregulated thymic regeneration. #ScienceNewsHighlights #ScienceMission https://lnkd.in/gPgh48xC https://lnkd.in/gxBv5Awv

Join this interesting webinar! ✅

𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 𝗵𝗮𝗲𝗺𝗼𝘀𝘁𝗮𝘀𝗶𝘀 𝘄𝗲𝗯𝗶𝗻𝗮𝗿: 𝗗-𝗱𝗶𝗺𝗲𝗿: 𝗔 𝗰𝗿𝘂𝗰𝗶𝗮𝗹 𝗺𝗮𝗿𝗸𝗲𝗿 𝗶𝗻 𝘁𝗵𝗿𝗼𝗺𝗯𝗼𝘁𝗶𝗰 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀 Gain key insights into the role of D-dimer in clinical practice: ✅ Understand why and when plasma D-dimer levels are elevated in patients and how to utilise D-dimer testing across various clinical conditions. ✅ Learn the diagnostic algorithms for managing and preventing DIC in septic patients, and explore approaches for handling conditions such as cancer, pregnancy, cardiovascular disease, or COVID-19. ✅ Discover the pros and cons of D-dimer testing and how it can enhance patient outcomes. Register here: https://lnkd.in/empVzu_b #Sysmex #Haemostasis #CaresphereAcademy

Did you know that therapeutic antibodies, while essential for treating many diseases, can cross the placenta and pose risks for a developing fetus? This has long limited their use during pregnancy. At #ImmunoBrain, while working on an immunotherapy drug for Alzheimer’s disease, I realized that its tailor-made design might also have an impact on the antibody ability to cross the placenta. To test this hypothesis, we made an experiment in pregnant mice, where we compared a standard therapeutic antibody with one that had a modified design. The results were striking: we observed a 100-fold reduction in placental penetration! This approach could enable safer antibody-based treatments during pregnancy, allowing women to manage chronic conditions or receive critical immunotherapies with a significantly lower risk for the fetal development. Although pregnancy is not a primary focus of our work at ImmunoBrain, I am grateful for the opportunity to explore innovative solutions and address an important unmet need. This idea ultimately led to a patent, which you can read more about here: WO2024233694A2 (https://lnkd.in/dvb956C6). I remain hopeful that a partner will advance this concept and realize its full potential. If this aligns with your interests or expertise, feel free to reach out. #Innovation #Immunotherapy #MaternalCare #PregnancySafety #AntibodyEngineering

Sickle cell disease is the most common genetic blood condition in the UK, affecting approximately 17,500 people. Women with sickle cell disease are at higher risk of having a sickle crisis during pregnancy (including pain or chest crises and stroke). What needs to change to improve care for patients with sickle cell? Improving education is the single most important change to enhance care for patients with sickle cell disease. By providing more information to decision-makers, we can ensure that necessary resources are allocated to improve patient care and support the pharmaceutical industry in developing new treatment options. Additionally, it is crucial to collaborate with healthcare professionals across the NHS to ensure that patients with sickle cell disease receive the care and compassion they deserve. This collaborative effort will help improve patient outcomes and overall quality of life. #research #care #sicklecelldisease

Sickle cell disease is the most common genetic blood condition in the UK, affecting approximately 17,500 people. Women with sickle cell disease are at higher risk of having a sickle crisis during pregnancy (including pain or chest crises and stroke). What needs to change to improve care for patients with sickle cell? Improving education is the single most important change to enhance care for patients with sickle cell disease. By providing more information to decision-makers, we can ensure that necessary resources are allocated to improve patient care and support the pharmaceutical industry in developing new treatment options. Additionally, it is crucial to collaborate with healthcare professionals across the NHS to ensure that patients with sickle cell disease receive the care and compassion they deserve. This collaborative effort will help improve patient outcomes and overall quality of life. #research #care #sicklecelldisease

To kick off our #AAD2025 session spotlight, we’re highlighting some of the inflammatory dermatoses sessions that will be featured at the 2025 AAD Annual Meeting. • Atopic Dermatitis (S052) - Amy S. Paller, MD, FAAD, will lead a discussion on the high burden, comorbidities, and emergent therapies for AD. • How to Approach Challenges in Hidradenitis Suppurativa Management (F013) - Jennifer Lin Hsiao, MD, FAAD, and Joslyn S. Kirby, MD, FAAD, will co-direct this session on managing HS in challenging scenarios, such as during pregnancy, the onset of comorbidities, or after multiple treatment failures. • Psoriasis: Modern Therapeutic Approaches (S058) - Bruce Elliot Strober, MD, PhD, FAAD, will review the updated AAD-National Psoriasis Foundation psoriasis guidelines, oral and biologic therapies, and the impact of therapy on comorbidities. Learn about these sessions and hundreds more in our AAD searchable program: https://lnkd.in/gWHFzwmf

FDA has approved levacetylleucine (Aqneursa—IntraBio) to treat Niemann-Pick disease type C (NPC), less than 1 week after authorizing another intervention for the rare genetic condition. Patients suffer progressive neurological symptoms and organ dysfunction. Aqneursa targets the neurological effects of the disease, as demonstrated in a 24-week crossover study involving 60 patients. Participants scored better on the functional Scale for the Assessment and Rating of Ataxia — which assesses gait, sitting, stance, and speech disturbance domains — during 12 weeks of Aqneursa therapy than during 12 weeks on placebo. The new drug is indicated for adults and children weighing 15 kg or more, but the prescribing information warns of a potential for embryo-fetal harm if used during pregnancy. Common adverse effects associated with the drug include abdominal pain, difficulty swallowing, upper respiratory tract infections, and vomiting. https://lnkd.in/eDGkZKpw

📢 Exciting new R package for pharmacoepidemiologists! Our team just published a pre-print on "Tame" - an R package for identifying complex medication use patterns. 📊💊 Key features: 🔹 Clusters medications based on timing, dose, and ATC codes 🔹 Captures real-world usage beyond simple "exposed/unexposed"  🔹 Helps detect potential safety signals and drug interactions 🔹 Useful for studying polypharmacy and treatment trajectories In the paper we describe the package and apply it to antidepressant use in pregnancy and adverse psychiatric post-partum outcomes. Check out the paper for more details on methodology and applications. The package is available on CRAN. This tool could enhance medication safety studies and improve our understanding of real-world pharmacoepidemiology. Excited to see how others may use it in their research! LINK: https://lnkd.in/dsqbDXs6 #Pharmacoepidemiology #RPackage #DrugSafety #DataScience

Quinolones are broad-spectrum antibiotics that inhibit bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication and transcription. They are effective against Gram-negative and some Gram-positive bacteria, making them useful in treating UTIs, respiratory, and gastrointestinal infections. However, overuse has led to rising resistance, limiting efficacy. Common agents include ciprofloxacin, levofloxacin, and moxifloxacin. They are generally well-tolerated but may cause side effects like GI upset, tendinitis, or CNS effects. Use cautiously in children and pregnancy. Monitor for drug interactions and resistance patterns to optimize therapy while minimizing risks